Trials / Completed
CompletedNCT03015324
Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors
Biological Effects of Maintenance Usage of Hydroxychloroquine on PAR-4 Levels in Patients With Resected Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Peng Wang, MD PhD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hydroxychloroquine will be administered on an outpatient basis within 12 weeks after primary surgery followed by adjuvant chemotherapy /or radiation therapy (if needed). Hydroxychloroquine will be administered orally at a dose of 400 mg daily for 90 days. Subjects will receive HCQ every day.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine | Hydroxychloroquine |
Timeline
- Start date
- 2017-08-08
- Primary completion
- 2020-02-03
- Completion
- 2021-02-02
- First posted
- 2017-01-10
- Last updated
- 2022-01-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03015324. Inclusion in this directory is not an endorsement.